Aims/hypothesis Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes, and this vascular impairment begins in childhood.
Introduction
Vascular disease is the major cause of morbidity and mortality in patients with type 1 diabetes [1] . The overall mortality of patients with type 1 diabetes is 50% within 40 years of diagnosis, compared with only 10% of a control population. This increased mortality is related to their risk of micro-and macrovascular disease, which occurs at an earlier age [2, 3] , and probably has its roots in childhood [4] . There is now compelling evidence that optimising glycaemic control with intensive diabetes management reduces the development and progression of microvascular complications [5] . The mechanisms of development of macrovascular disease are complex and multifactorial, and include contributions from conventional adult risk factors such as hypertension and hyperlipidaemia [6] .
More recently, attention has focused on the early detection of abnormal physiology that may predict a high risk of vascular disease in type 1 diabetes. Attention has been drawn to the role of the endothelium in diabetes, and its interactions with the white blood cell and other mechanisms of oxidative stress [7] . Our group has previously described that endothelial dysfunction is an early event in type 1 diabetes, with abnormalities present in children with type 1 diabetes even when no clinical signs of vascular complications are present [8] [9] [10] . Additionally, we have shown that these early changes in endothelial dysfunction in young people are related to glycaemic control and diabetes duration [9] .
Intensive diabetes management involves intensive insulin therapy (IIT) with either a multiple daily injection regimen or with a continuous subcutaneous insulin infusion via a pump. IIT is associated with a significant improvement in glycaemic control and a reduction of the development and progression of microvascular complications including retinopathy [5] . However, IIT is successful only when coupled with increased health professional support such as increased clinic visits and frequent telephone contact [5] . This is reflected in current UK guidelines for the management of type 1 diabetes, which advocate that IIT should be delivered as part of a comprehensive support package [11, 12] . However, increasing traditional contact between health professionals and patients is expensive to deliver within current health service resources. We therefore developed 'Sweet Talk', a novel motivational support network, using text messages to deliver a theoretically guided behavioural intervention to facilitate uptake of IIT in young people. This has been described in detail previously [13, 14] . Thus, the aims of the current study were to investigate the impact of introducing intensive diabetes management in young people with type 1 diabetes on markers of endothelial function and skin microvascular reactivity, which we have shown previously to be impaired in young people with type 1 diabetes and to be related to glycaemic control [9] . It is known that microvascular abnormalities demonstrable in the skin are related to increased vascular risk [15, 16] .
Methods
Participants The Tayside Medical Ethics Research Committee granted approval for this study and recruitment took place between October 2002 and February 2003. All patients (n=131) attending paediatric diabetes clinics in Tayside, Scotland who were aged between 8 and 18 years, had type 1 diabetes for >1 year and were on conventional insulin therapy (CIT; two or three daily injections of premixed insulin), were considered for inclusion in the trial. Five patients were excluded from participation because they were thought unsuitable for IIT (two had serious social problems, one had autism, one had severe needle phobia and one was moving away from the area). Informed consent was obtained from the 92 patients who elected to participate in the study and from their parents. No patients were taking vasoactive medication or other therapy, such as statins, thought to affect vascular function. All children in the study over the age of 12 years had been screened regularly for microvascular complications, according to national guidelines [12] . A small number (<20%) had background retinopathy only. None had microalbuminuria or hypertension (although 24 h blood pressure monitoring was not undertaken in this group).
Study protocol A computer-generated concealed allocation sequence (with block randomisation that balanced at 6, 12, 30 and simple randomisation after 30) assigned participants to one of three groups: group 1, a control group continuing with CIT and usual support; group 2, continuing with CIT and receiving the text message behavioural support intervention; and group 3, changing to IIT and receiving the text message behavioural support intervention. The study did not include a group with IIT and usual support, because the literature indicates that introducing IIT without increasing support is unsuccessful [17] . Patients on CIT received two injections of pre-mixed insulin (Mixtard 30; NovoNordisk Copenhagen, Denmark) with or without one injection of insulin aspart to cover the evening meal (Novorapid; NovoNordisk). Patients on ITT received either basal bolus therapy or insulin pump therapy and carbohydrate-counting education. Patients opting for pump therapy used the Medtronic 508 (Minimed, Watford, UK) pump with the rapid-acting insulin aspart. Pump therapy was initiated as an outpatient in half-day group pump start sessions run by the diabetes team. Patients choosing basal bolus therapy used glargine (Lantus; Sanofi-Aventis, Paris, France) as the once-daily basal insulin and insulin aspart as the bolus insulin to cover carbohydrate content of meals. All patients continued with conventional care delivered by a multidisciplinary team including clinics every 3-4 months and access to an emergency hotline. Patients allocated to the Sweet Talk intervention participated in goal setting at clinic visits and received one or two text messages daily containing tips, information and reminders to reinforce their personal diabetes self-management goal.
Biochemical analysis Venous blood was taken from each patient at the beginning and end of the 12 month study period between 0900 and 1100 hours on each occasion to avoid diurnal variation in the measurements. Discomfort was minimised by the use of local anaesthetic cream. HbA 1c was analysed by Bayer DCA 2000 (Newbury, UK; normal range 4.2-6.5%). A venous blood sample was obtained from the antecubital fossa using a 23 gauge butterfly needle. Citrated blood was placed immediately into ice and centrifuged within 30 min at 1,500×g for 15 min at 4°C and aliquots were stored at −70°C for measurement of E-selectin by ELISA (R&D Systems, Abingdon, UK).
Ten millilitres of blood were collected into EDTA and prepared as before for the measurement of the various lipids. All lipids (cholesterol, HDL, LDL and triacylglycerols) were measured on a centrifugal analyser using products from Randox Laboratories (Crumlin, UK).
Microvascular measurements were conducted in a laboratory at an environmental temperature of 22±1°C. Participants were seated with their arms supported at heart level. We assessed microvascular function, as described previously [18] , by measuring the volar forearm skin blood flow responses to iontophoresis of acetylcholine (ACh; Sigma-Aldrich, Poole, UK) and sodium nitroprusside (SNP; David Bull Laboratories, Warwick, UK), which are endothelium-dependent and endothelium-independent vasodilators, respectively. At the time of the ethics committee review, due consideration was given to the use of the Sigma ACh preparation, which is a chemical not intended for human use. Iontophoresis is a drug-delivery method, which stimulates the migration of charged ions across the skin non-invasively and without inducing systemic effects.
A single iontophoresis chamber (Moor Instruments, Axminster, UK), consisting of a Perspex ring of internal diameter 20 mm with a wire electrode running round its inner surface, was fixed to the skin with adhesive tape. The hydrochloride salt of ACh was dissolved in deionised water to produce a 1% (w/v) solution, and 2 ml of this solution were used to fill the chamber. We use deionised water as the vehicle as we have shown that this does not produce competition for delivery of ions [19] . The positive lead of an iontophoresis controller (MIC2; Moor Instruments) was connected to the chamber, and the negative lead attached to a conductive hydro-gel pad on the wrist, which served as the reference electrode. We used a delivery current of 100 mA, and administered a successive accumulation of 20, 40 and 80 s doses of Ach, effectively 2, 4 and 8 mC (millicoulombs). Using a current of 100 μA and large diameter electrodes does not elicit vasodilatation via nonspecific, galvanic effects, because a low charge density (maximum of 2.5 × 10 −2 mC/mm 2 ) is generated. The resulting changes in microvascular skin blood flow were assessed at each delivery site using laser Doppler imaging (Moor LDI; Moor Instruments). This technique works by scanning a 2 mW helium-neon laser across the surface of the skin. Light that is backscattered from moving erythrocytes undergoes a shift in frequency proportional to their velocity, according to the Doppler principle. The resulting colour-coded image represents skin blood flow over the scan area, a relative measure called the laser Doppler flux. A baseline image was recorded at the start. After each iontophoretic delivery, the solution was removed and the chamber dried, and then three images were recorded at 30 s intervals as the response developed. This was repeated for each dose of ACh. The experiment was repeated at an adjacent site with 1% (w/v) SNP, dissolved in deionised water. The iontophoresis leads were reversed for SNP because it is negatively charged in solution, and five images were recorded at 45 s intervals after each dose because SNP takes longer to have an effect on blood flow. The laser Doppler images were analysed using dedicated software (Moor Instruments), and we calculated the median laser Doppler flux over the iontophoresis delivery site for each one. For the response to each dose, the mean of the two stable flux values was taken, and this was divided by the baseline measurement to give a ratio representing the change in flow. This combination of iontophoresis and laser Doppler imaging has been used successfully by us and others in Values are medians (interquartile range) a Postcodes were used to obtain the Carstairs deprivation score, which was based on results from the 2001 census. A higher score represents a higher level of deprivation No significant differences in categorical variables using χ 2 or continuous variables using ANOVA were identified SDS, standard deviation score many studies [20, 21] , and the good reproducibility of the technique has been confirmed [22, 23] . A recent study showed that skin microvascular responses to iontophoretically applied ACh strongly correlated with flow-mediated dilatation responses in the brachial artery [24] . Values for HbA1 c are means±SD, the remainder are medians (interquartile range) Responses to ACh were significantly greater after intervention with ITT and Sweet Talk compared with the other two groups at all concentrations tested 9.8-8.1%. Data for microvascular responses were not normally distributed and were therefore log 10 -transformed to achieve normality. Differences in the dose-response to ACh and SNP before and after each particular intervention were tested across the three groups using a three-way ANOVA model for repeated measures. In addition, comparisons between the absolute changes (before vs after) in microvascular responses across the three different groups were compared using ANOVA. Post hoc analysis used the Bonferroni test. Correlations were performed using the Spearman rank method. In all cases, significance was acknowledged if the probability of a type 1 error was <5% (i.e. p<0.05). With respect to microvascular function, the power calculation is based on repeat measurements at two time-points at least 2 months apart in 44 individuals. The SD of the change for the ACh response (defined as the ratio of response over baseline) is 0.80. Therefore we are able to detect a difference of 0.5 SDs (which equates to a 13.4% change) with 80% power at p<0.05 change using a paired comparison in 25 patients. We have previously shown that n=29 patients are sufficient to detect differences of 14% between 11-to 14-year-old children with low and high 2 h glucose levels [18] . Additionally we have shown that n=28 is sufficient to show improvements of 29% in normal individuals before and after intervention [25] .
Statistical analysis
The blood results were also not normally distributed and Wilcoxon signed rank tests were performed to compare differences between the levels at visit 1 and visit 2. The values in Table 4 are the median levels and the 25th and 75th percentiles.
Outcome data were compared with baseline. Data analysis was performed on an intention-to-treat basis. The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Ninety-two patients were recruited over a 5 month period from October 2002 and each patient was enrolled in the study for 1 year. There were no significant differences in baseline demographic or clinical characteristics between the patients who declined to participate in the study and those who enrolled, and there were no differences between the groups at baseline (Table 1) . One patient withdrew from group 1 after randomisation, and one patient from group 2 moved from the area. Three patients from group 1, and five from group 2 were changed to ITT during the study for clinical reasons. Of the 31 patients allocated to group 3, 22 chose an insulin pump and nine chose basal bolus therapy. Of these, two patients remained on CIT, and three patients changed from pump therapy to CIT during the year of the study. All participants were analysed on an intention-totreat basis. Flow through the study is illustrated in Fig. 1 .
Glycaemic control deteriorated in patients on CIT, but improved significantly in patients allocated to IIT (p=0.007, ANOVA). IIT (group 3) was associated with significantly greater improvements in E-selectin, a key endothelial marker, elevated levels of which have been linked to future cardiovascular events [26] ; this was statistically significant (p<0.0001) over the CIT (group 1 p=0.026; group 2 p= 0.053, ANOVA). Table 2 shows the baseline values for microvascular responses to ACh and SNP in the three groups. There was a trend for microvascular responses to be higher in group 2 (CIT+text message support) compared with responses in the other two groups (p=0.094 for ACh and p=0.03 for SNP), which were accounted for by differences in the male to female ratios. Correcting for sex showed that the trends for ACh and SNP responses to be greater in group 2 were no longer apparent (p=0.226 for ACh and p=0.11 for SNP).
There were no significant correlations between any of the clinical variables, such as duration of diabetes, HbA 1c , insulin dose) and microvascular responses to ACh and SNP. Table 2 and Fig. 2 show that in comparison with the changes in microvascular responses to ACh in groups 1 and 2, group 3, who received IIT and text messaging support, showed a significant improvement in microvascular response to ACh (p=0.017, ANOVA). At the two highest doses of ACh, microvascular responses increased by 11.4 and 14.8% compared with pre-intervention values, respectively. In addition, comparing the absolute before vs after differences in ACh responses among the three groups showed that the IIT group had the greatest improvement compared with the other two groups (p=0.003, ANOVA; Table 3 ). There was no significant change in vascular responses to SNP before and after intervention in any of the groups. There was no correlation between the improvement in vascular responses to ACh and the lowering of HbA 1c levels in group 3. Table 4 shows the results of markers of endothelial dysfunction and activation. It was not possible to obtain the full volume of blood required for these tests from all patients, so the number of patients for whom data were available is also indicated. There were no significant differences in lipid profiles (cholesterol, triacylglycerols, HDL or LDL) between the groups at baseline or end of the study.
Discussion
Patients receiving intensive diabetes management, comprising ITT and Sweet Talk intensive support, showed significant improvements in glycaemic control compared with the groups allocated to CIT regimens. The overall reduction of 1.1% when adjusted for baseline (from 10.2 to 9.2%) is of clinical significance as it is associated with approximately a 40% reduction in risk of developing microvascular complications [27] . Patients treated with ITT showed significant improvements in E-selectin levels, which confirms findings of a previous study, which showed that improvements in E-selectin correlate with improvements in glycaemic control [28] . The ITT and Sweet Talk groups showed significant improvements in endothelial-dependent (ACh) microvascular responses, which were independent of improvements in glycaemic control, possibly suggesting that intensive therapy may modify endothelial dysfunction by additional means. In our view this is consistent with results from the Diabetes Control and Complications Trial, where it has been suggested that the ITT itself, compared with conventional therapy, confers an additional benefit over and above any improvement in glycaemic control [29] . The mechanisms of endothelial damage in diabetes are incompletely understood at present, but it seems unlikely that ambient glucose levels are a sole factor. Insulin modulates endothelial function including vascular reactivity, thrombotic processes and inflammation. Therefore ITT may confer its advantages by delivering a more physiological insulin profile together with the reduction in glycaemic excursions. Other factors including smoking habit and hypertension may have influenced vascular outcome, but these data are not available.
Future research should aim to determine whether vascular function is influenced by the mechanism of intensive insulin delivery (pump therapy or basal bolus therapy). Furthermore, longitudinal studies are needed to determine whether the improvements in glycaemic control can be maintained, and whether the improvements in markers of endothelial function and vascular control translate into a reduction in the development of the micro-and macrovascular complications of diabetes.
In conclusion, these novel findings suggest that intensive diabetes management improves metabolic control, endothelial function and microvascular reactivity in young people with type 1 diabetes. This has important consequences for future management of these children. Confirmed surrogate markers for future cardiovascular events are favourably altered by such an intensive regimen. The improvements in vascular markers appear to occur independently of improvements in glycaemic control, suggesting that IIT confers additional vascular protection, possibly by delivering a more physiological insulin profile, which is important because of the reduction in glycaemic excursion, and because insulin is a vasodilator with potent anti-inflammatory effects. This study supports the early introduction of intensive therapy in young people with diabetes, as reducing the antecedents of angiopathy will translate into significant health advantages in adulthood.
